Modifying factors in urinary bladder carcinogenesis by Ito, Nobuyuki et al.
Environmental Health Perspectives
VoL 49, pp. 217-222, 1983
Modifying Factors in Urinary Bladder
Carcinogenesis
by Nobuyuki Ito,* Shoji Fukushima,* Tomoyuki Shirai,*
Keisuke Nakanishi,* Ryohei Hasegawa*
and Katsumi Imaida*
N-Butyl-N(4-hydroxybutyl)nitrosamine (BBN) is a potent carcinogen in the urinary bladder of ani-
mals. The BBN model of bladder cancer is an excellent model of human urinary bladder cancer and
has already led to a greater knowledge of its pathogenesis. In our studies, histogenesis and morpho-
logical characteristics of BBN urinary bladder cancer were analyzed in different animal species
such as rats, mice, hamsters and guinea pigs and also in different rat strains. Papillary or nodular
hyperplasia (PN hyperplasia) is found to be a preneoplastic lesion of the rat urinary bladder. There-
fore, the promoting and inhibitory effects of various chemicals in two-stage urinary bladder carcino-
genesis were judged by measuring PN hyperplasia in rats. Dose-dependent and organ-specific ef-
fects of the urinary bladder promoter, saccharin, in the induction of PN hyperplasia were shown in
rats after initiation by BBN. The promoting effect of saccharin was seen more clearly in the urinary
bladder of rats after potent initiation. A strain difference in susceptibility of the urinary bladder to
the promoter was also shown. These results suggest that the above various factors may also have
modifying activities on urinary bladder carcinogenesis in man.
Introduction
Animal models are very useful for studying the
pathogenesis of human diseases. We have used rats
given a carcinogen, N-butyl-N-4-hydroxybutyl)nitro-
samine (BBN) in their drinking water as a model of
urinary bladder cancer for more than ten years.
This has proved to be a very good model of human
bladder cancer and has provided much information
on its pathogenesis. This paper describes the histo-
genesis and morphological characteristics of BBN
urinary bladder cancer in rats and factors modify-
ing BBN bladder carcinogenesis.
Urinary Bladder Carcinogenesis
by BBN
BBN is a potent carcinogen in the urinary blad-
der of animals, and there are many reports on its
carcinogenicity in rat urinary bladder (1). Histologi-
cal lesions in the urinary bladder of rats induced by
BBN were classified into four types: simple hyper-
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plasia, papillary or nodular hyperplasia (PN hyper-
plasia), papilloma and cancer. PN hyperplasia of the
urinary bladder in rats treated with 0.05% BBN de-
veloped before the induction of papilloma or cancer.
The urinary bladders of rats treated with various
doses of BBN for different periods were examined
histologically to determine the incidence of PN hy-
perplasia and cancer. A high dose of BBN induced
high incidences of PN hyperplasia and cancer in a
short period. Dose-response relationships were oW
served for the induction of PN hyperplasia and can-
cer, the dose of BBN, and the period of BBN treat-
ment. Moreover, a good correlation was found be-
tween the inductions of PN hyperplasia and cancer
with different doses of BBN. Thus, it is clear that
PN hyperplasia is a preneoplastic lesion of rat uri-
nary bladder.
The histological types and grades of 611 urinary
bladder cancers induced in rats by BBN were ana-
lyzed (2). Most of the cancers (95.4%) were transi-
tional cell carcinomas, the remainder being squa-
mous cell carcinomas (3.3%), undifferentiated carci-
nomas (1.0%) and carcinosarcomas (0.3%). Among
the transitional cell carcinomas, 23.3% were Grade
I anaplasias, 55.% Grade II and 21.5% Grade III.
Some of the transitional cell carcinonmas had areasof squamous metaplasia and/or glandular meta-
plasia, and the incidence of metaplasia increased
with the grade of anaplasia. There was a significant
relation between the grade of transitional cell carci-
nomas and their extent of invasion into the bladder
wall. More Grade I carcinomas were noninvasive,
and one-third of Grade II were invasive. Of the tran-
sitional cell carcinomas of Grade III, 24.8% were
noninvasive, 48.0% invaded the submucosa, and
13.6% invaded the muscle layer and through the se-
rosa. Thus, there was a clear relation between the
incidence of invasive transitional cell carcinomas in-
duced by BBN and the grade. These results show
that the morphological characteristics of bladder
cancers in rats induced by BBN resemble those of
human bladder cancer. BBN is also very useful in
studies on factors modifying bladder carcinogenesis.
Synergistic and Additive Effects of
BBN, 2-AAF, FANFT and 3,3 '*DCB
The synergistic and additive effects of subcarcin-
ogenic doses of chemicals may be important in hu-
man carcinogenesis, since several carcinogens are
present in our environment at low concentrations.
Experimentally, some chemical carcinogens have
been shown to have synergistic and additive effects
in chemical carcinogenesis when administered in
combination or in sequence with other carcinogenic
chemicals.
Whether BBN, 2-acetylaminofluorene (2-AAF), N-
[4-(5-nitro-2-furyl)2-thiazolyl]formamide (FANFT)
and 3, 3'-dichlorobenzidine(3,3'-DCB) have synergis-
tic or additive effects on the urinary bladder when
administered to rats at subcarcinogenic doses was
also studied (3, 4).
The incidence of PN hyperplasia of the bladder
epithelium was significantly higher in groups
treated with BBN plus FANFT, BBN plus 3,3'-DCB,
BBN plus 2-AAF, and BBN plus 3,3'-DCB plus
2-AAF than in those treated with BBN, FANFT,
3,3'-DCB, or 2-AAF alone (Table 1). It was also
higher in the group treated with 2-AAF plus
FANFT than in that treated with 2-AAF alone. The
incidence of papilloma was significantly higher in
the group treated with BBN plus FANFT than in
those treated with BBN or FANFT alone, and it
was higher in the group treated with BBN plus 2-
AAF than in those treated with BBN or 2-AAF
alone. The incidence of transitional cell carcinoma
was significantly higher in the group treated with
BBN plus FANFT than in the group treated with
BBN only. Thus synergistic effects on bladder tu-
morigenesis were observed on administration of
BBN with FANFT, 2-AAF and/or 3,3'-DCB. The ef-
fects of BBN and FANFT were most synergistic.
The effects of sequential administrations of BBN,
2-AAF, FANFT and 3,3'-DCB at subcarcinogenic
doses on urinary bladder carcinogenesis were exam-
ined in male Wistar rats (Table 2). Chemicals were
each administered for 4 weeks in various sequences.
No bladder carcinomas were present in rats given
only BBN or any one of the other three chemicals.
The incidences of bladder carcinomas were in-
creased significantly by sequential administration of
all four chemicals or the first three chemicals, with-
out 3,3'-DCB. Bladder cancer also developed in rats
administered FANFT, 2-AAF and 3,3'-DCB in se-
Table 1. Synergistic effects on urinary bladder carcinogenesis in rats of treatment with BBN, 2-AAF,
FANFT and 3,3'-DCB for 40 weeks.
Changes in urinary bladder, 0/
Cancer
Effective With
no. of PN No. of squamous With
Group Treatmenta rats hyperplasia Papilloma rats metaplasia invasion
1 BBN 16 1 (6.3) 0 - 0 - 0 - 0 -
2 2-AAF 13 0 - 0 - 0 - 0 - 0 -
3 FANFT 11 1 (9.1) 1 ( 9.1) 0 - 0 - 0 -
4 3,3'-DCB 16 0 - 0 - 0 - 0 - 0 -
5 BBN + 2-AAF 11 9( 81.8)* 6(54.5)* 1 ( 9.1) 0 - 0 -
6 BBN + FANFT 11 11 (100.0)* 10 (90.0)* 3 (27.3)** 2 ( 66.7) 1 ( 33.3)
7 BBN + 3,3'-DCB 7 5 ( 71.4)* 1 (14.3) 1 (14.3) 0 - 1(100.0)
8 2-AAF + FANFT 14 6 ( 42.9)* 1 ( 7.1) 0 - 0 - 0 -
9 2-AAF + 3,3'-DCB 8 1 ( 12.5) 1 (12.5) 1 ( 12.5) 1(100.0) 0 -
10 BBN + 3,3'-DCB + 2-AAF 10 8 ( 80.0)* 2 (20.0) 1 (10.0) 0 - 0 -
11 Control 12 0 - 0 - 0 - 0 - 0-
aBBN: 0.001% N-butyl-N-(4-hydroxybutyl)nitrosamine in drinking water; 2-AAF: 0.0050/ 2-acetylaminofluorene in diet; FANFT:
0.04% N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in diet; 3,3'-DCB: 0.030/ 3,3'-dichlorobenzidine in diet.
*Significantly different from the groups treated with the respective carcinogens singly, atp<0.01.
**Significantly different from group 1 at p<0.05.
218 ITO ETAL.FACTORS IN URINARYBLADDER CARCINOGENESIS
Table 2. Additive effects of BBN, FANFT, 2-AAF and/or 3,3'-DCB on urinary bladder carcinogenesis in rats.
Changes in urinary bladder, %
Cancer
Effective With
no. of PN No. of squamous With
Group Treatmenta rats hyperplasia Papilloma rats metaplasia invasion
1 BBN 20 8(40.0) 5(25.0) 0 - 0 - 0 -
2 BBN+FANFT 20 13 (65.0) 11 (55.0) 3 (15.0) 1 (33.3) 1 (33.3)
3 BBN+FANFT+2-AAF 19 11 (57.9) 7 (36.8) 5 (26.3)** 0 - 2 (40.0)
4 BBN+FANFT+2-AAF+3,3'-DCB 20 12 (60.0) 9 (45.0) 6 (30.0)* 1 (16.7) 2 (33.3)
5 FANFT 17 1 ( 5.9) 0 - 0 - 0 - 0 -
6 FANFT+2-AAF 19 2 (10.5) 0 - 0 - 0 - 0 -
7 FANFT+2-AAF+3,3'-DCB 20 4 (20.0) 1 ( 5.0) 1 ( 5.0) 0 - 0 -
8 2-AAF 19 0 - 0 - 0 - 0 - 0 -
9 2-AAF+3,3'-DCB 18 1 ( 5.6) 0 - 0 - 0 - 0 -
10 3,3'-DCB 19 0 - 0 - 0 - 0 - 0 -
11 Control 12 0 - 0 - 0 - 0 - 0-
aBBN: 0.01% N-butyl-N-(4-hydroxybutyl)nitrosamine in drinking water; FANFT: 0.15% N-[4-(5-nitro-2-furyl)-2-thiazolyl]forma-
mide in diet; 2-AAF: 0.025% 2-acetylaminofluorene in diet; 3,3'-DCB: 0.03% 3,3'-dichlorobenzidine in diet.
*Significantly different from the incidence in group 1 (p<0.02).
**Significantly different from group 1 at (p<0.01).
quence. No antagonistic effects of the chemicals
were observed.
Promoting Effects of Various
Chemicals in Two-Stage Urinary
Bladder Carcinogenesis
Saccharin and tryptophan are known to act as
promoters after initiation of urinary bladder carcin-
ogenesis with carcinogens (5). Various chemicals are
present in the environment and many human can-
cers are attributable to environmental factors. Thus
since some of the environmental chemicals to which
humans are exposed may promote urinary bladder
carcinogenesis, special consideration should be paid
to evaluation of their promoting activities. Carcino-
genesis of the urinary bladder was initiated in male
6-week-old F344 or Wistar rats by adding 0.01%
BBN to their drinking water for 4 weeks, and then
the animals were given 16 test chemicals to exam-
ine their respective promoting activities (6). The in-
cidence and number of PN hyperplasias per 10 cm
of basement membrane were measured with a color
video image processor. Administration of 5.0% sac-
charin significantly increased the incidence and
number of PN hyperplasias. This finding could be
related to the induction of cancers in rat urinary
bladder by high levels of saccharin. Sodium ascor-
bate, D-tryptophan, allopurinol and diphenyl also
increased the numbers of PN hyperplasias signifi-
cantly, but other test chemicals, such as acetazola-
mide, quercetin, cyclamate, o-phenylphenol and caf-
feine, did not. The results suggest that sodium as-
corbate, allopurinol and diphenyl have promoting
activities in urinary bladder carcinogenesis in rats.
The results indicating that sodium ascorbate is a
promoter in urinary bladder carcinogenesis are con-
sistent with other experiments.
In general, chemical carcinogens show dose-
response relations for both tumor induction and the
length of the induction period. Studies were made
on the dose-response to saccharin as a promoter in
induction of preneoplastic lesions of the urinary
bladder (7). F344 rats of both sexes were initiated
by adding 0.01% BBN to their drinking water for 4
weeks and were then given diets containing sac-
charin at various concentrations for 32 weeks and
killed at the end of week 36. The incidences and av-
erage numbers of PN hyperplasia per 10 cm of base-
ment membrane in males with a dose of 5.0% sac-
charin and in females with doses of 5.0% and 1.0%
were significantly higher than those with BBN
alone. Plots of the incidence of PN hyperplasia
against the dose of saccharin gave parabolic curves
in both sexes (Fig. 1); these dose-response curves
showed enhanced hyperplastic responses in both
sexes given 0.2 to 5.0% saccharin. The results sug-
gest that if the experimental period had been
longer, a dose-response relationship for the induc-
tion of papilloma and cancer might have been ob-
served.
The organ specific effects of two different tumor
promoters were investigated in a two-stage carcino-
genesis experiment (8). In the initiation stage, the
rats were given 0.02% 2-AAF in the diet for 4
weeks or 0.01% BBN in the drinking water for 4
weeks. Then, in the promotion stage, they were
given 0.05% phenobarbital in the diet or 5.0% sac-
charin in the diet for 32 weeks. Phenobarbital great-
ly enhanced hepatocarcinogenesis and induced hepa-
tocellular carcinoma after 2-AAF treatment, and it
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FIGURE 1. Dose-response curve for incidence of PN hyper-
plasia in rat urinary bladder.
significantly increased formation of hyperplastic
liver nodules after BBN treatment. Saccharin sig-
nificantly enhanced the induction of PN hyper-
plasias of the urinary bladder after BBN or 2-AAF
treatment (Table 3). However, after 2-AAF or BBN
treatment, there was no effect of phenobarbital on
the urinary bladder or of saccharin on liver neo-
plasia induction. These data indicate that although
2-AAF and BBN have tumor-initiating effects in
both liver and urinary bladder, the tumor-promot-
ing effects of phenobarbital and saccharin are organ
specific.
Strain difference is one of the factors that modify
chemical carcinogenesis. Strain differences appear
to modify promotion as well as initiation in two-
stage carcinogenesis. Therefore, we tested whether
there was any strain difference in the effect of sac-
charin as a promoter. Male ACI, Wistar, F344 and
Sprague-Dawley (SD) rats were given a diet with
5.0% saccharin for 52 weeks (9). Histological exami-
nation showed that saccharin induced urinary blad-
der lesions in ACI rats, but no changes in Wistar,
F344 or SD rats. PN hyperplasia and papilloma
were increased significantly in the urinary bladder
of ACI rats given saccharin. Scanning electron mi-
croscopy showed mucosal foci with slightly elevated
cells, giving a cobblestone appearance, on the lumi-
nal surface of the urinary bladder. The superficial
epithelial cells were covered with short, uniform mi-
crovilli and with ropy or leafy microridges. In addi-
tion, several superficial epithelial cells with pleo-
morphic microvilli on their luminal surface were
found in these foci, as described previously. Among
the groups given saccharin, the ACI rats had the
greatest changes as shown by scanning electron mi-
croscopy. Slight formation of pleomorphic microvilli
and short, uniform microvilli were seen in Wistar
and F344 rats treated with saccharin, but not in SD
rats. Thus, there was a clear strain difference in
rats in susceptibility of the urinary bladder to sac-
charin. It is suggested that the promoting effect of
saccharin in the urinary bladder was greatest in
ACI rats.
Inhibitory Effects of Aromatic
Retinoic Acid, OK*432 and DDPM
on Urinary Bladder Carcinogenesis
of Rats
There have been many reports that vitamin A
and its analogs inhibit tumor induction in many or-
Table 3. Histopathologic changes of the urinary bladder in rats treated with 2-AAF or BBN followed by PB or SS.
PN hyperplasia Papilloma
Simple No./10 cm No./10 cm
No. of hyperplasia, basement basement
Group Treatmenta rats incidence, % Incidence, % membraneb Incidence, % membraneb
1A 2-AAF +PB 24 0 - 0 - 0 0 - 0
1B 2-AAF + SS 29 6 (21)** 4 (14)** 0.3 ± 1.1 0 - 0
iC 2-AAF 28 0 - 0 - 0 0- 0
2A BBN + PB 30 19 (63) 14 (47) 0.6 ± 0.7 9 (30) 0.4 ± 0.8
2B BBN + SS 29 27 (93)** 24 (83)** 2.6 ± 2.2* 6 (21) 0.2 ± 0.4
2C BBN 28 19 (68) 11 (39) 0.7 ± 1.0 8 (29) 0.4 ± 0.7
3A PB 29 0 - 0 - 0 0- 0
3B SS 28 0 - 0 - 0 0- 0
3C Control 29 0 - 0 - 0 0 - 0
a2-AAF: 0.02% 2-acetylaminofluorene in diet; BBN: 0.01% N-butyl-N-(4-hydroxybutyl)nitrosamine in drinking water; PB: 0.05%
phenobarbital in diet; SS: 5.0% sodium saccharin in diet.
bValues are means ± SD.
**p<0.05 compared with subgroup C (basal diet).
*p<O.Ol compared with subgroup C (basal diet).
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gans, such as the mammary gland, skin, urinary
bladder, lung, bronchus, forestomach and colon. The
inhibitory effect of an aromatic retinoic acid analog,
ethyl all-trans-944-methoxy-2,3,6-trimethylphenyl)
3,7-dimethyl-2,4,6,8-nonatetraenoate, on bladder car-
cinogenesis in rats treated with BBN was evaluated
(10). When given after BBN, 50 ppm of the aromatic
retinoid greatly reduced the incidence and number
of papillomas, and slightly inhibited the develop-
ment of cancer. Administration of 100 ppm of the
aromatic retinoid after BBN treatment also greatly
reduced the incidences and numbers of papillomas
and cancers. These results show that the aromatic
retinoid inhibits bladder carcinogenesis of rats
induced by BBN.
The relationship of immune status in patients
with cancer of the urinary bladder at various stages
of the disease has not been clearly defined, but it
appears that there is a gradual decrease in the im-
mune responsiveness of the patient as the disease
progresses. OK-432 is a streptococcal preparation
that enhances cellular immune and reticuloendo-
thelial responsiveness to tumors. The effect of im-
munostimulation by OK-432 on bladder carcinogene-
sis in rats was evaluated by using the carcinogens
(11). Short-term subcutaneous administration of OK-
432 after BBN did not affect bladder carcinogenesis,
but if OK432 treatment was begun after BBN treat-
ment and continued until the end of the experiment,
the incidence of BBN-induced bladder tumor was
significantly reduced. These results suggest that
OK432 may have a tumor inhibitory effect during
bladder carcinogenesis but that its effect is revers-
ible.
4,4'-Diaminodiphenylmethane (DDPM) is a potent,
selective, aromatic hepatotoxic agent. It induces
marked bile duct proliferation in the liver of rats
like a-naphthylisothiocyanate (ANI). ANI reduced
the incidence of bladder tumors when fed to rats
either before or during the administration of blad-
der carcinogens (12). Thus, the hepatotoxic agent
that produced bile duct proliferation had significant
inhibitory effects on bladder tumorigenesis induced
by chemical carcinogens. We examined the effects
of administration of hepatotoxic agents after carcin-
ogen treatment on the development of bladder tu-
mors in rats (13). Rats were given drinking water
containing 0.01% BBN for 4 weeks and then 0.1%
DDPM in their diet for 34 weeks. DDPM reduced
the induction of papillomas of the bladder as mea-
sured by the incidence and number/10 cm basement
membrane, although it did not inhibit the induction
of PN hyperplasia of the bladder. These results indi-
cate that DDPM administration in the "post-initia-
tion" stage inhibited bladder carcinogenesis in rats.
Conclusions
BBN-induced rat bladder cancers resemble hu-
man bladder cancers in morphological characteris-
tics and there appear to be several close parallels
between the human disease and rat models. 2-AAF
is also a suitable bladder carcinogen to use experi-
mentally, although it is less carcinogenic than BBN
in the rat bladder. These carcinogens should be use-
ful in experimental assessment of the etiology, pre-
vention, and therapy of human bladder cancer.
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